

News



### Extended linkage with the Netherlands Cancer Registry

Despite decreases in cancer death rates, the number of new cancer cases is expected to more than double worldwide over the next two decades. Due to growth and aging of the population, it is estimated that by 2030 there will be about 26 million new cancer cases and 17 million cancer deaths per year globally. Currently, there is growing consensus that real-world data should play a significant role in both pre- and post-market regulatory decisions by means of pharmacoepidemiologic studies.

[Read more →](#)

Events



### Volv Global and the PHARMO Institute partner for patient-level prediction modelling for rare diseases

We are proud to announce our new strategic partnership with Volv Global. The aim of this collaboration is to improve the identification of patients with rare diseases. Due to the complexity and rareness of these diseases, diagnosing a patient is often a lengthy process which puts a burden on the patient's life and the healthcare system. By supporting physicians in this process, patients will be diagnosed earlier and the risk of misdiagnosis is reduced. As a result, patients will be in uncertainty for less time and have faster access to treatment, which could positively influence disease progression.

[Read more →](#)

Publications

### Annual report 2017



Our annual report for 2017 is out! Last year 38 articles based on data from the PHARMO Database Network were published in peer reviewed journals and we presented our data and studies at seven different conferences. In 2017 we collaborated with our European partners in sixteen different studies. Next to these highlights we included a more detailed description of a few of our key publications of last year. This and more is summarised in our annual report 2017.

[Read more →](#)